130 related articles for article (PubMed ID: 32682156)
1. Design, synthesis and SARs of novel telomerase inhibitors based on BIBR1532.
Liu C; Zhou H; Sheng XB; Liu XH; Chen FH
Bioorg Chem; 2020 Sep; 102():104077. PubMed ID: 32682156
[TBL] [Abstract][Full Text] [Related]
2. Contributory role of microRNAs in anti-cancer effects of small molecule inhibitor of telomerase (BIBR1532) on acute promyelocytic leukemia cell line.
Pourbagheri-Sigaroodi A; Bashash D; Safaroghli-Azar A; Farshi-Paraasghari M; Momeny M; Mansoor FN; Ghaffari SH
Eur J Pharmacol; 2019 Mar; 846():49-62. PubMed ID: 30658112
[TBL] [Abstract][Full Text] [Related]
3. Effects of telomerase inhibitor on epigenetic chromatin modification enzymes in malignancies.
Biray Avci C; Dogan F; Ozates Ay NP; Goker Bagca B; Abbaszadeh Z; Gunduz C
J Cell Biochem; 2018 Dec; 119(12):9817-9824. PubMed ID: 30145821
[TBL] [Abstract][Full Text] [Related]
4. BIBR1532, a Selective Telomerase Inhibitor, Enhances Radiosensitivity of Non-Small Cell Lung Cancer Through Increasing Telomere Dysfunction and ATM/CHK1 Inhibition.
Ding X; Cheng J; Pang Q; Wei X; Zhang X; Wang P; Yuan Z; Qian D
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):861-874. PubMed ID: 31419512
[TBL] [Abstract][Full Text] [Related]
5. Telomerase inhibition regulates EMT mechanism in breast cancer stem cells.
Kusoglu A; Goker Bagca B; Ozates Ay NP; Gunduz C; Biray Avci C
Gene; 2020 Oct; 759():145001. PubMed ID: 32738420
[TBL] [Abstract][Full Text] [Related]
6. A Non-Toxic Concentration of Telomerase Inhibitor BIBR1532 Fails to Reduce
Pandya VA; Crerar H; Mitchell JS; Patani R
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33806803
[TBL] [Abstract][Full Text] [Related]
7. A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines.
Shi Y; Sun L; Chen G; Zheng D; Li L; Wei W
Target Oncol; 2015 Dec; 10(4):565-73. PubMed ID: 25916999
[TBL] [Abstract][Full Text] [Related]
8. Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity.
Rankin AM; Faller DV; Spanjaard RA
Anticancer Drugs; 2008 Apr; 19(4):329-38. PubMed ID: 18454043
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological preconditioning by TERT inhibitor BIBR1532 confers neuronal ischemic tolerance through TERT-mediated transcriptional reprogramming.
Xie X; Li M; Zhou M; Chow SF; Tsang CK
J Neurochem; 2021 Nov; 159(4):690-709. PubMed ID: 34532857
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate.
Pascolo E; Wenz C; Lingner J; Hauel N; Priepke H; Kauffmann I; Garin-Chesa P; Rettig WJ; Damm K; Schnapp A
J Biol Chem; 2002 May; 277(18):15566-72. PubMed ID: 11854300
[TBL] [Abstract][Full Text] [Related]
11. Structural Basis of Telomerase Inhibition by the Highly Specific BIBR1532.
Bryan C; Rice C; Hoffman H; Harkisheimer M; Sweeney M; Skordalakes E
Structure; 2015 Oct; 23(10):1934-1942. PubMed ID: 26365799
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of telomerase using BIBR1532 enhances doxorubicin-induced apoptosis in pre-B acute lymphoblastic leukemia cells.
Bashash D; Zareii M; Safaroghli-Azar A; Omrani MD; Ghaffari SH
Hematology; 2017 Jul; 22(6):330-340. PubMed ID: 28054503
[TBL] [Abstract][Full Text] [Related]
13. Optimization of the TRAP assay to evaluate specificity of telomerase inhibitors.
Piotrowska K; Kleideiter E; Mürdter TE; Taetz S; Baldes C; Schaefer U; Lehr CM; Klotz U
Lab Invest; 2005 Dec; 85(12):1565-9. PubMed ID: 16170334
[TBL] [Abstract][Full Text] [Related]
14. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532.
El-Daly H; Kull M; Zimmermann S; Pantic M; Waller CF; Martens UM
Blood; 2005 Feb; 105(4):1742-9. PubMed ID: 15507522
[TBL] [Abstract][Full Text] [Related]
15. Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors.
Mueller S; Hartmann U; Mayer F; Balabanov S; Hartmann JT; Brummendorf TH; Bokemeyer C
Invest New Drugs; 2007 Dec; 25(6):519-24. PubMed ID: 17534576
[TBL] [Abstract][Full Text] [Related]
16. Targeted inhibition of telomerase activity combined with chemotherapy demonstrates synergy in eliminating ovarian cancer spheroid-forming cells.
Meng E; Taylor B; Ray A; Shevde LA; Rocconi RP
Gynecol Oncol; 2012 Mar; 124(3):598-605. PubMed ID: 22115853
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, biological evaluation, drug-likeness, and in silico screening of novel benzylidene-hydrazone analogues as small molecule anticancer agents.
Alam MS; Lee DU
Arch Pharm Res; 2016 Feb; 39(2):191-201. PubMed ID: 26694484
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of telomerase causes vulnerability to endoplasmic reticulum stress-induced neuronal cell death.
Hosoi T; Nakatsu K; Shimamoto A; Tahara H; Ozawa K
Neurosci Lett; 2016 Aug; 629():241-244. PubMed ID: 27443785
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of telomerase by BIBR 1532 and related analogues.
Barma DK; Elayadi A; Falck JR; Corey DR
Bioorg Med Chem Lett; 2003 Apr; 13(7):1333-6. PubMed ID: 12657276
[TBL] [Abstract][Full Text] [Related]
20. [The influence of compound aITEL1296 on telomerase activity and the growth of cancer cells].
Kovalenko NA; Zhdanov DD; Bibikova MV; Gotovtseva VIu
Biomed Khim; 2011; 57(5):501-10. PubMed ID: 22629600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
